Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Group 1 - Prime Medicine, Inc. closed its underwritten public offering of 43,700,000 shares of common stock at a price of $3.30 per share, raising approximately $144.2 million in gross proceeds before expenses [1] - The offering included the full exercise of the underwriters' option to purchase an additional 5,700,000 shares, with no discounts or commissions for 1,818,181 shares sold to the Cystic Fibrosis Foundation [1] - TD Cowen and BMO Capital Markets served as joint book-running managers for the offering [2] Group 2 - The shares were offered under an effective shelf registration statement filed with the SEC on November 3, 2023, and declared effective on November 13, 2023 [3] - A final prospectus supplement detailing the terms of the offering was filed with the SEC and is available on their website [3] Group 3 - Prime Medicine is focused on developing a new class of one-time curative genetic therapies using its proprietary Prime Editing platform, which aims for precise and efficient gene editing [6] - The company is advancing a diversified portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology, targeting diseases with well-understood biology [7]